Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 11/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | SCN1A | P35498 | 3/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18484178 | 1.00 | TNF (0.41) | TNFPIK3CDEGFRPIK3CGSCN1A | |
| SCHEMBL18484164 | 0.83 | PIK3CD (0.39) | TNFPIK3CDPIK3CGSCN1ASCN5A | |
| SCHEMBL19205792 | 0.83 | PIK3CD (0.39) | TNFPIK3CDPIK3CGSCN1ASCN5A | |
| SCHEMBL19205811 | 0.80 | SCN1A (0.41) | TNFPIK3CDPIK3CGSCN1ASCN5A | |
| SCHEMBL19205810 | 0.80 | SCN1A (0.41) | TNFPIK3CDPIK3CGSCN1ASCN5A | |
| SCHEMBL19205663 | 0.77 | SOS1 (0.39) | TNFPIK3CDEGFRPIK3CGSCN1A | |
| SCHEMBL19205662 | 0.77 | SOS1 (0.39) | TNFPIK3CDEGFRPIK3CGSCN1A | |
| SCHEMBL18484100 | 0.76 | KMT2A (0.44) | SCN1ASCN5ASCN8A | |
| SCHEMBL18484101 | 0.76 | KMT2A (0.44) | SCN1ASCN5ASCN8A | |
| SCHEMBL18484175 | 0.73 | PIK3CD (0.37) | TNFPIK3CDSCN1ASCN5ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| EP-3331863-B1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-08-23 | — | — | US | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
| WO-2017021879-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988467-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | TNF 386/4885PIK3CD 3634/4885EGFR 2748/4885 |
| US-10344024-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | TNF 386/4885PIK3CD 3634/4885EGFR 2748/4885 |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | TNF 437/4885PIK3CD 3730/4885EGFR 2927/4885 |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | TNF 465/4885PIK3CD 4313/4885EGFR 3176/4885 |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | TNF 437/4885PIK3CD 3730/4885EGFR 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.